BPG is committed to discovery and dissemination of knowledge
Articles in Press
8/25/2026 9:20:13 AM | Browse: 15 | Download: 1
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Basic Study |
| Article Title |
EPZ020411, a PRMT6 inhibitor, suppresses colorectal cancer cell proliferation, migration, and invasion through targeting the TGM2/MAPK axis
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yu-Zhong Chen, Jia Liu, Ya-Ping Wang, Jun Du, Jia-Chi Ma and Gong-Sheng Jin |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Anhui Provincial University Scientific Research Project |
2023AH051989 |
| Anhui Provincial Department of Education Faculty Development Program for Early- and Mid-Career Academics |
JWFX2024022 |
| Doctoral Research Start-Up Fund of the First Affiliated Hospital of Bengbu Medical University |
2024-CYZ |
|
| Corresponding Author |
Yu-Zhong Chen, MD, PhD, Department of Surgical Oncology, The First Affiliated Hospital of Bengbu Medical University, No. 287 Changhuai Street, Longzihu District, Bengbu 233000, Anhui Province, China. cyz0903@foxmail.com |
| Key Words |
Colorectal cancer; EPZ020411; Protein arginine methyltransferase 6; Transglutaminase 2; Mitogen-activated protein kinases |
| Core Tip |
In this study, we have found that EPZ020411 suppresses the growth and metastasis of colorectal cancer (CRC) cells. Mechanistically, EPZ020411 downregulates transglutaminase 2 (TGM2) and inhibits the JNK/p38 mitogen-activated protein kinases (MAPK) signaling pathway. Notably, TGM2 overexpression partially reverses these effects, highlighting its critical role as a downstream mediator. Overall, this study identified a novel protein arginine methyltransferase 6 (PRMT6)-TGM2-MAPK regulatory axis and provided a preliminary experimental basis for the potential of targeting PRMT6 in CRC, and new insights into the potential of targeting PRMT6 as a therapeutic strategy for CRC. |
| Citation |
Chen YZ, Liu J, Wang YP, Du J, Ma JC, Jin GS. EPZ020411, a PRMT6 inhibitor, suppresses colorectal cancer cell proliferation, migration, and invasion through targeting the TGM2/MAPK axis. World J Gastrointest Oncol 2026; In press
|
| PDF |
123745-in-press.pdf
|
 |
Received |
|
2026-06-02 10:17 |
|
Peer-Review Started |
|
2026-06-02 10:18 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2026-06-23 08:42 |
|
Revised |
|
2026-07-07 06:28 |
|
Publication Fee Transferred |
|
2026-07-25 08:52 |
|
Second Decision by Editor |
|
2026-08-25 02:47 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-08-25 09:20 |
|
Articles in Press |
|
2026-08-25 09:20 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
|
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
